Protein modification by the conjugation of ubiquitin moietiesubiquitination-plays a major part in many biological processes, including cell cycle and apoptosis 1 . The enzymes that mediate ubiquitin-conjugation have been well-studied, but much less is known about the ubiquitin-specific proteases that mediate deubiquitination of cellular substrates 2, 3 . To study this gene family, we designed a collection of RNA interference vectors to suppress 50 human de-ubiquitinating enzymes, and used these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD) 4 , having no known function, enhances activation of the transcription factor NF-kB. We show that CYLD binds to the NEMO (also known as IKKg) component of the IkB kinase (IKK) complex, and appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. We show that this effect can be relieved by aspirin derivatives that inhibit NF-kB activity 5 , which suggests a therapeutic intervention strategy to restore growth control in patients suffering from familial cylindromatosis.
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The family of de-ubiquitinating enzymes (DUBs) consists of ubiquitin carboxy-terminal hydrolases and ubiquitin-specific processing proteases [1] [2] [3] . A role for DUB genes in cancer is suggested by the fact that this family contains both oncogenes 6, 7 and tumour suppressor genes 4 . The strategy we pursued to study the function of the family of DUB enzymes was to inhibit expression of individual family members through RNA interference and search for phenotypes. A total of 50 genes containing the conserved catalytic domain of DUB enzymes could be identified in sequence databases (Fig. 1a , and Supplementary Information). We retrieved the complementary DNA sequences, and selected four unique 19-mer sequences from each transcript for cloning into pSUPER, a vector that mediates suppression of gene expression through synthesis of short hairpin RNAs having small interfering RNA (siRNA)-like properties 8 . We chose to make four knockdown vectors against each DUB to increase the chance that a significant inhibition of DUB expression would be obtained. In total, we made 200 knockdown vectors, which were subsequently pooled into 50 sets of 4 vectors, where each set of vectors was designed to target a single DUB transcript (Fig. 1a) .
To ask how effective sets of four knockdown vectors inhibited DUB gene expression, we fused the open reading frame of four of the DUBs to green fluorescent protein (GFP) and determined the levels of GFP-DUB fusion protein expression in the absence and presence of co-expression of the DUB knockdown vectors. A significant reduction in protein levels was induced by all four DUB knockdown vector pools, whereas control p21-red fluorescent protein (RFP) fusion protein was unaffected (Fig. 1b) . We conclude that this strategy allows efficient inhibition of DUB expression.
To study members of the DUB family, we asked if suppression of DUBs affected the activity of NF-kB, a transcription factor involved in inflammation, immune responses and protection against apoptosis 9 . We transfected an NF-kB-luciferase reporter gene, together with each of the 50 sets of 4 DUB knockdown vectors into human U2-OS cells, and measured the effect of DUB knockdown on tumour necrosis factor-a (TNF-a)-activation of NF-kB. Only one of the sets of DUB knockdown vectors (no. 36) enhanced TNF-a-activation of NF-kB (Fig. 1c) . Importantly, the DUB no. 36 set of knockdown vectors targets the cylindromatosis tumour suppressor gene CYLD 4 (see Supplementary Information) . Levels of haemagglutinin (HA)-CYLD protein levels were significantly reduced by the most active of the four knockdown vectors (pSU-PER-CYLD) (Fig. 1d) . CYLD knockdown did not enhance basal level of NF-kB activity, but caused a further increase in NF-kB activation by phorbol 12-myristate 13-acetate (PMA) (Fig. 1e) . This indicates that CYLD loss activates NF-kB in response to diverse stimuli. Together, these data suggest that CYLD is an NF-kB regulator.
NF-kB is inactivated by IkB proteins. Signalling through the IkB kinase (IKK) complex, containing the IkB kinases IKKa and b and the structural component NEMO (or IKKg), causes phosphorylation and subsequent degradation of IkB, allowing activation of NF-kB 9, 10 . The observed effect of CYLD on NF-kB activity could result from an effect of CYLD on the TNF-a receptor, the TNFreceptor-associated factor (TRAF) proteins, a downstream effect on the IKK complex or on the IkB/NF-kB complex. To address this, we asked if CYLD associates with members of the NF-kB signalling machinery. We found that CYLD co-immunoprecipitated with NEMO ( Fig. 2a) . Since CYLD interacts with NEMO in a yeast two hybrid assay (see accompanying manuscript 11 ), this is likely to be direct. However, owing to the lower expression of IkBa and IKKb (Fig. 2a) , we cannot exclude the possibility that CYLD also interacts with other components of the IKK complex.
To study the effect of CYLD on IKK activity, we measured IKKb activity in an in vitro kinase assay. In the absence of TNF-a no IKKb kinase activity towards IkBa could be detected (Fig. 2b) . As expected, TNF-a treatment stimulated IKKb kinase activity. Importantly, this activity was enhanced when cells were co-transfected with pSUPER-CYLD (compare Fig. 2b , lanes 5, 6) . No effects were seen of CYLD knockdown on IKKb protein levels (Fig. 2b , lower panel), suggesting that CYLD does not regulate IKKb abundance. Consistent with increased IKKb kinase activity by pSUPER-CYLD, we observed that CYLD knockdown resulted in a reduction in IkBa levels, an endogenous substrate of IKKb kinase (Fig. 2c ). This decrease in IkBa level occurs without TNF-a treatment, indicating that there might be some IKK activity in U2-OS cells under the tissue culture conditions used, or that CYLD is required to maintain shut-off of IKK signalling in the absence of activating signals. These data indicate that CYLD acts as an antagonist of the IKK complex that binds to the NEMO component, and that a reduction in CYLD stimulates IKK-activity. A prediction from these data is that expression of a catalytically inactive mutant of CYLD will also cause a reduction of the IkBa levels through competition with endogenous CYLD. Figure 2d shows that transfection of cells with a point mutant of CYLD in which the active site cysteine is mutated 7 causes a similar reduction in IkBa levels as seen with pSUPER-CYLD (compare Fig. 2d, lanes 2 and 4) . We conclude that the de-ubiquitinating enzyme activity of CYLD is required to act on NF-kB.
TNF receptor-associated factors (TRAFs) are involved in cytokine-mediated activation of NF-kB 12, 13 . NF-kB-inducing activity of TRAF2 and TRAF6 requires their ubiquitin ligase activity and non-destructive lysine-63 poly-ubiquitination 14, 15 . Their ubiquitination during TNF signalling makes these proteins candidate substrates for CYLD. We co-transfected TRAF2 and HA-ubiquitin expression vectors, and monitored levels of TRAF2 ubiquitination in the presence of both wild-type CYLD and an active site mutant letters to nature of CYLD. Figure 2e shows that TRAF2 is ubiquitinated, in agreement with the notion that TRAF2 over-expression leads to activation of NF-kB 11 . Importantly, co-expression of wild-type CYLD caused a reduction in TRAF2 ubiquitination, and an active site mutant of CYLD markedly increased levels of ubiquitinated TRAF2 (Fig. 2e) . Although these results do not rule out the possibility that CYLD could have other targets in the pathway, or that the effects seen on TRAF2 ubiquitination are indirect, they are consistent with a model in which the effect of CYLD on NF-kB activation is mediated by CYLD-dependent de-ubiquitination of TRAF2.
When combined with inhibitors of transcription or translation, TNF-a can be a potent inducer of apoptosis [16] [17] [18] [19] . This pro-apoptotic activity of TNF-a can be inhibited by activation of NF-kB, which activates a number of anti-apoptotic genes 20 . Since CYLD knockdown stimulates PMA-induced activation of NF-kB, we asked if CYLD and PMA also collaborate to inhibit TNF-a-induced apoptosis. HeLa cells were treated with TNF-a in the presence of cycloheximide (CHX) to induce apoptosis both with and without pre-treatment with PMA, which stimulates expression of antiapoptotic NF-kB target genes (see Methods). letters to nature resulted in an even larger fraction of surviving cells, suggesting that CYLD loss can be anti-apoptotic (Fig. 3a, b) , probably through enhanced activation of NF-kB. Consistent with this, CYLD knockdown and PMA also collaborated in NF-kB activation in HeLa cells (Fig. 3c) .
NF-kB can be inhibited by a number of pharmacological agents, including sodium salicylate (an aspirin derivative) and prostaglandin A1 (PGA1) 5, 21 . Both inhibit IKKb, the kinase which is hyper-activated as a result of CYLD knockdown (Fig. 2b) . To address whether the effect of CYLD knockdown on NF-kB activation can be counteracted by sodium salicylate or PGA1, we transfected U2-OS cells with the NF-kB-reporter and stimulated NF-kB with PMA. As observed before, pSUPER-CYLD enhanced PMA-stimulated NF-kB activity (Fig. 4a, b) . This effect of CYLD knockdown on NF-kB could be suppressed by both sodium salicylate and PGA1 (Fig. 4a, b) , indicating that these compounds can compensate for CYLD suppression in this assay.
It is likely that loss of CYLD confers resistance to apoptosis through activation of NF-kB. If correct, the protective effect of CYLD knockdown could be reversed by the NF-kB inhibitor sodium salicylate. We tested this by treating HeLa cells with PMA in the presence or absence of pSUPER-CYLD. Apoptosis was induced by the addition of TNF-a and CHX. CYLD knockdown and PMA treatment again conferred resistance to TNF-a-induced apoptosis (Fig. 4c) . Exposure of cells to sodium salicylate abolished the protective effect of CYLD knockdown on apoptosis (Fig. 4c ). This indicates that CYLD loss is anti-apoptotic through the activation of IKKb and subsequently NF-kB. We describe here a high-throughput RNA interference screen in mammalian cells to identify novel regulators of NF-kB. We focused on ubiquitin-specific processing proteases, as these proteins are antagonists of the ubiquitin conjugating enzymes and ubiquitin ligases. We identified the familial cylindromatosis tumour suppressor gene (CYLD) as a novel negative regulator of NF-kB, thus establishing the first (to our knowledge) direct link between the NF-kB signalling cascade and a tumour suppressor gene. We propose a model in which CYLD functions to turn TNF-receptor signalling off by removing ubiquitin from TRAF2 (Fig. 4d) . Although CYLD may have other targets than NF-kB, we suggest that the deregulated proliferation in the skin appendages in familial cylindromatosis results from a mild shift in the balance between proliferation and apoptosis in favour of proliferation. This is supported by the observation that most cylindromas have a diploid karyotype and are rarely metastatic 4 . In the vast majority of cell types, activation of NF-kB is an oncogenic event 9 . However, it has recently been shown that inhibition of NF-kB in keratinocytes contributes to neoplasia 22 . Importantly, cylindromas are not derived from keratinocytes but from hair follicles and exocrine glands 23 . These skin appendages require NF-kB activity, as mice with suppressed NF-kB have defects in the development of these tissues due to increased apoptosis 24, 25 . Our observation that enhanced protection from apoptosis resulting from CYLD suppression can be reversed by simple pharmacological agents like sodium salicylate and prostaglandin A1 suggests a strategy to restore normal growth control in patients suffering from familial cylindromatosis. We are currently testing this in a clinical trial using topical application of aspirin derivatives on cylindromas.
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Methods

Materials, antibodies, and plasmid construction
To generate DUB knockdown vectors, four annealed sets of oligonucleotides encoding short hairpin transcripts corresponding to one DUB enzyme (see Supplementary Information) were cloned individually into pSUPER. Bacterial colonies were pooled and used for plasmid preparation. To generate GFP-DUB fusion proteins, the corresponding DUB enzymes were PCR amplified and cloned into pEGFP-N1 (Clontech). pNF-kB-Luc vector was obtained from Clontech, SV40-Renilla from Promega. PMA, TNF-a, prostaglandin A1 and cycloheximide were purchased from Sigma. HA-tagged CYLD was PCR amplified, and cloned into pCDNA 3.1 (-), Flag tagged NEMO was generated by cloning an EcoRI-XbaI NEMO containing fragment into pcDNA-flag. Anti-IkBa (c-21) and HA tag (Y-11) antibodies were obtained from Santa Cruz, anti-Flag M2 from Sigma and anti-GFP rabbit polyclonal serum was provided by J. Neefjes.
Cell cultures, transient transfections and reporter assays
All cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. High efficiency electroporation of cells was done as described 26 . Reporter assays were carried out using calcium phosphate transfection of 0.5 mg NF-kBLuc, 1 ng SV40-Renilla and 2.5 mg pSUPER vectors. Forty-eight hours after transfection, cells were stimulated with 200 nM PMA or 20 ng ml 21 TNF-a and luciferase activity was measured 72 hours after transfection. Sodium salicylate (10 mM) or prostaglandin A1 (8 mM) was added to the cells 48 hours after transfection, and reporter activity was measured 72 hours after transfection. In HeLa cells, NF-kB activity was measured 2 hours after PMA stimulation.
Immunoblotting, immunoprecipitation and kinase assay
Western blots were performed using whole cell extracts, separated on 8-12% SDS-PAGE gels and transferred to polyvinylidine difluoride membranes (Millipore). Western blots were probed with the indicated antibodies. HEK293 cells were transfected by calcium phosphate precipitation with the indicated plasmids; 48 hours after transfection cells were lysed in ELB buffer (0.25 M NaCl, 0.1% NP-40, 50 mM HEPES pH 7.3) supplemented with 'Complete' protease inhibitors (Roche), and protein complexes were immunoprecipitated with 2 mg of the indicated antibodies conjugated to protein G sepharose beads. To detect TRAF2 ubiquitination, immunoprecipitations were performed using RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid and 0.1% SDS). Immunoprecipitation/kinase assays were performed essentially as described 27 .
Apoptosis assays
Experimental design. In the experiments described in Figs 3 and 4 , we first treat cells with PMA or PMA in the presence of CYLD knockdown for 2-3 hours. This allows NF-kB to become active and stimulate expression of the anti-apoptotic NF-kB target genes. Then we add TNF-a and CHX at the same time. The CHX is added because TNF-a has two effects; it induces apoptosis in a transcription-independent fashion, and induces NF-kB to protect from apoptosis, which requires transcription. By adding CHX and TNF-a at the same time, the anti-apoptotic effects of TNF-a are blocked (by CHX), leaving only the apoptotic signalling pathway intact. This is why combined treatment with TNF-a and CHX is such a powerful inducer of apoptosis. Thus, in this experimental set-up the apoptotic effects of TNF-a can only be rescued by activation of NF-kB target genes prior to CHX treatment (that is, through the combined effects of PMA þ CYLD knockdown).
Seventy-two hours after electroporation of HeLa cells with the indicated plasmids, cells were treated with 200 nM PMA for 2-3 hours to stimulate NF-kB activity, followed by a 12-hour incubation in medium containing both 10 ng ml 21 TNF-a and 10 mg ml 21 CHX to induce apoptosis. Viable cells were quantified using the Trypan blue exclusion method. To inhibit NF-kB activity, medium was supplemented with 10 mM sodium salicylate 3.5 hours before TNF-a addition.
